AbCellera Biologics (ABCL) PT Lowered to $49 at Credit Suisse
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $12.70 +0.40%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $49.00 (from $51.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral
- Mphasis Ltd. (MPHL:IN) PT Lowered to INR2,970 at UBS
- Paychex (PAYX) PT Lowered to $105 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
